Literature DB >> 27552404

Oncologic Safety of Laparoscopy in the Surgical Treatment of Type II Endometrial Cancer.

Giovanni Favero1, Cristina Anton, Xin Le, Alexandre Silva E Silva, Nasuh Utku Dogan, Tatiana Pfiffer, Christhardt Köhler, Edmund Chada Baracat, Jesus Paula Carvalho.   

Abstract

BACKGROUND: Laparoscopy is considered the method of choice in the operative treatment of type I endometrial carcinoma (EC). However, there is a paucity of data regarding the safety of endoscopy for type II EC because these malignancies have several biological similarities with ovarian cancer.
OBJECTIVES: This study aimed to evaluate the feasibility, operative outcomes, and oncologic safety of laparoscopic surgery in patients with type II EC.
METHODS: A retrospective study with histologically confirmed serous or clear-cell EC without peritoneal carcinomatosis treated by laparoscopy (G1) or laparotomy (G2) was conducted. Procedures included hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymphadenectomy.
RESULTS: From 2009 to 2015, 89 patients were included; 53 women underwent laparoscopy and 36 underwent laparotomy. No relevant epidemiological or oncologic difference between groups was observed. The mean number of removed pelvic nodes was 16 [±10] and 12 [±13] in group 1 (G1) and group 2 (G2), respectively (P = 0.127). The mean number of dissected para-aortic nodes was significantly greater in the laparoscopic group (11 [±9] vs 6 [±9], P = 0.006). Para-aortic metastasis was significantly more often observed in the endoscopy group (26% vs 13%, P = 0.04). Adjuvant therapies were given to 86% of the patients in the study and 75% in the control group (P = 0.157). No excessive blood loss, casualty related to surgery, intraoperative complication, or conversion to laparotomy occurred in G1. Ten (18%) women from G1 and 36% (13/36) in G2 developed relevant postoperative complications (P = 0.03). The median duration of follow-up was 38 months for the laparoscopy and 47 months for the open surgery (P = 0.12). The 5-year overall and disease-free survival were similar, 86% versus 78% and 58% versus 51% for G1 and G2, respectively (P = 0.312).
CONCLUSIONS: Laparoscopy is oncologically at least not inferior to laparotomy for the surgical treatment of type II EC. Endoscopic techniques are feasible, effective, result in significantly less morbidity, and improved quality staging. Although statistical significance was not reached, laparoscopy was associated with superior oncologic results.

Entities:  

Mesh:

Year:  2016        PMID: 27552404     DOI: 10.1097/IGC.0000000000000803

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  Laparoscopic surgery for low, intermediate and high-risk endometrial cancer.

Authors:  Mehmet Ali Vardar; Umran Kucukgoz Gulec; Ahmet Baris Guzel; Derya Gumurdulu; Ghanim Khatib; Gulsah Seydaoglu
Journal:  J Gynecol Oncol       Date:  2018-11-16       Impact factor: 4.401

3.  Comparison of survival and perioperative outcomes following simple and radical hysterectomy for stage II endometrial cancer: a single-institution, retrospective, matched-pair analysis.

Authors:  Yahui Jiang; Nan Jia; Menghan Zhu; Yuan He; Xiaoxia Che; Tianjiao Lv; Weiwei Feng
Journal:  J Int Med Res       Date:  2019-07-29       Impact factor: 1.671

4.  [Non endometroid endometrial cancer guidelines evaluation: A multicentric retrospective study].

Authors:  Antoine Scattarelli; Albane Poteau; Moutaz Aziz; Marick Lae; Philippe Courville; Maxime Arnaud; Loic Marpeau; Benoit Resch
Journal:  Bull Cancer       Date:  2020-10-06       Impact factor: 1.276

5.  Could the Long-Term Oncological Safety of Laparoscopic Surgery in Low-Risk Endometrial Cancer also Be Valid for the High-Intermediate- and High-Risk Patients? A Multi-Center Turkish Gynecologic Oncology Group Study Conducted with 2745 Endometrial Cancer Cases. (TRSGO-End-001).

Authors:  Mehmet Ali Vardar; Ahmet Baris Guzel; Salih Taskin; Mete Gungor; Nejat Ozgul; Coskun Salman; Umran Kucukgoz-Gulec; Ghanim Khatib; Cagatay Taskiran; Ilkkan Dünder; Firat Ortac; Kunter Yuce; Cosan Terek; Tayup Simsek; Aydın Ozsaran; Anil Onan; Gonca Coban; Samet Topuz; Fuat Demirkiran; Ozguc Takmaz; M Faruk Kose; Ahmet Gocmen; Gulsah Seydaoglu; Derya Gumurdulu; Ali Ayhan
Journal:  Curr Oncol       Date:  2021-10-29       Impact factor: 3.677

6.  Survival after laparoscopy versus laparotomy for apparent early-stage uterine clear cell carcinoma: Results of a large multicenter cohort study.

Authors:  Chengyu Shui; Lin Ran; Yong Tian; Li Qin; Xin Gu; Hui Xu; Cui Hu; Lin-Lin Zhang; You Xu; Chen Cheng; Wu Huan
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

7.  Introduction of robotic surgery for endometrial cancer into a Brazilian cancer service: a randomized trial evaluating perioperative clinical outcomes and costs.

Authors:  Alexandre Silva E Silva; João Paulo Mancusi de Carvalho; Cristina Anton; Rodrigo Pinto Fernandes; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.